Diagnosis and Treatment of Invasive Candidiasis

<i>Candida</i> species, belonging to commensal microbial communities in humans, cause opportunistic infections in individuals with impaired immunity. Pathogens encountered in more than 90% cases of invasive candidiasis include <i>C. albicans</i>, <i>C. glabrata, C. krus...

Full description

Bibliographic Details
Main Authors: Natalia Barantsevich, Elena Barantsevich
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/11/6/718
_version_ 1797490682441498624
author Natalia Barantsevich
Elena Barantsevich
author_facet Natalia Barantsevich
Elena Barantsevich
author_sort Natalia Barantsevich
collection DOAJ
description <i>Candida</i> species, belonging to commensal microbial communities in humans, cause opportunistic infections in individuals with impaired immunity. Pathogens encountered in more than 90% cases of invasive candidiasis include <i>C. albicans</i>, <i>C. glabrata, C. krusei, C. tropicalis</i>, and <i>C. parapsilosis</i>. The most frequently diagnosed invasive infection is candidemia. About 50% of candidemia cases result in deep-seated infection due to hematogenous spread. The sensitivity of blood cultures in autopsy-proven invasive candidiasis ranges from 21% to 71%. Non-cultural methods (beta-D-glucan, T2Candida assays), especially beta-D-glucan in combination with procalcitonin, appear promising in the exclusion of invasive candidiasis with high sensitivity (98%) and negative predictive value (95%). There is currently a clear deficiency in approved sensitive and precise diagnostic techniques. Omics technologies seem promising, though require further development and study. Therapeutic options for invasive candidiasis are generally limited to four classes of systemic antifungals (polyenes, antimetabolite 5-fluorocytosine, azoles, echinocandins) with the two latter being highly effective and well-tolerated and hence the most widely used. Principles and methods of treatment are discussed in this review. The emergence of pan-drug-resistant <i>C. auris</i> strains indicates an insufficient choice of available medications. Further surveillance, alongside the development of diagnostic and therapeutic methods, is essential.
first_indexed 2024-03-10T00:36:31Z
format Article
id doaj.art-8a0ab400361f464a85d231838d117ce3
institution Directory Open Access Journal
issn 2079-6382
language English
last_indexed 2024-03-10T00:36:31Z
publishDate 2022-05-01
publisher MDPI AG
record_format Article
series Antibiotics
spelling doaj.art-8a0ab400361f464a85d231838d117ce32023-11-23T15:16:06ZengMDPI AGAntibiotics2079-63822022-05-0111671810.3390/antibiotics11060718Diagnosis and Treatment of Invasive CandidiasisNatalia Barantsevich0Elena Barantsevich1Almazov National Madical Research Centre, Research Department of Microbiology and Nosocomial Indfections, Akkuratova, 2, 197341 Saint-Petersburg, RussiaAlmazov National Madical Research Centre, Research Department of Microbiology and Nosocomial Indfections, Akkuratova, 2, 197341 Saint-Petersburg, Russia<i>Candida</i> species, belonging to commensal microbial communities in humans, cause opportunistic infections in individuals with impaired immunity. Pathogens encountered in more than 90% cases of invasive candidiasis include <i>C. albicans</i>, <i>C. glabrata, C. krusei, C. tropicalis</i>, and <i>C. parapsilosis</i>. The most frequently diagnosed invasive infection is candidemia. About 50% of candidemia cases result in deep-seated infection due to hematogenous spread. The sensitivity of blood cultures in autopsy-proven invasive candidiasis ranges from 21% to 71%. Non-cultural methods (beta-D-glucan, T2Candida assays), especially beta-D-glucan in combination with procalcitonin, appear promising in the exclusion of invasive candidiasis with high sensitivity (98%) and negative predictive value (95%). There is currently a clear deficiency in approved sensitive and precise diagnostic techniques. Omics technologies seem promising, though require further development and study. Therapeutic options for invasive candidiasis are generally limited to four classes of systemic antifungals (polyenes, antimetabolite 5-fluorocytosine, azoles, echinocandins) with the two latter being highly effective and well-tolerated and hence the most widely used. Principles and methods of treatment are discussed in this review. The emergence of pan-drug-resistant <i>C. auris</i> strains indicates an insufficient choice of available medications. Further surveillance, alongside the development of diagnostic and therapeutic methods, is essential.https://www.mdpi.com/2079-6382/11/6/718<i>Candida</i>diagnostic testsbeta-D-glucanT2Candidamannanprocalcitonin
spellingShingle Natalia Barantsevich
Elena Barantsevich
Diagnosis and Treatment of Invasive Candidiasis
Antibiotics
<i>Candida</i>
diagnostic tests
beta-D-glucan
T2Candida
mannan
procalcitonin
title Diagnosis and Treatment of Invasive Candidiasis
title_full Diagnosis and Treatment of Invasive Candidiasis
title_fullStr Diagnosis and Treatment of Invasive Candidiasis
title_full_unstemmed Diagnosis and Treatment of Invasive Candidiasis
title_short Diagnosis and Treatment of Invasive Candidiasis
title_sort diagnosis and treatment of invasive candidiasis
topic <i>Candida</i>
diagnostic tests
beta-D-glucan
T2Candida
mannan
procalcitonin
url https://www.mdpi.com/2079-6382/11/6/718
work_keys_str_mv AT nataliabarantsevich diagnosisandtreatmentofinvasivecandidiasis
AT elenabarantsevich diagnosisandtreatmentofinvasivecandidiasis